Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The front-runner coronavirus vaccine appears to protect people from symptomatic disease.
The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.
New Yorker Alejandrina Peña had hepatitis C—until a great doctor and powerful new treatment gave her a fresh start.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
A daily dose of the growth factor analogue administered over 24 weeks also aided in NASH resolution.
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
A fifth of the worldwide population with fatty liver disease consists of lean people.
Health advocate David Whiters has mastered some smooth moves since overcoming addiction and hep C.
During a clinical trial for a new hep C treatment, David Whiters got cured.
Clinical trials often exclude key patient populations, including children and people living with HIV or hepatitis B or C.
Encourage wider participation of children, people with HIV and those with brain metastasis.
As pharmaceutical companies race to develop treatments for NASH, they find one thing is missing: willing test subjects.
Clinical trial findings from the 2017 Liver Meeting
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.